WO2008029877A1 - agent anti-vieillissement, agent de blanchiment cutané, agent antioxydant et agent anti-inflammatoire - Google Patents

agent anti-vieillissement, agent de blanchiment cutané, agent antioxydant et agent anti-inflammatoire Download PDF

Info

Publication number
WO2008029877A1
WO2008029877A1 PCT/JP2007/067402 JP2007067402W WO2008029877A1 WO 2008029877 A1 WO2008029877 A1 WO 2008029877A1 JP 2007067402 W JP2007067402 W JP 2007067402W WO 2008029877 A1 WO2008029877 A1 WO 2008029877A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
agent
mass
skin
added
Prior art date
Application number
PCT/JP2007/067402
Other languages
English (en)
Japanese (ja)
Inventor
Hiroko Kikuchi
Masaki Arashima
Hiroko Yoshida
Original Assignee
Noevir Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co., Ltd. filed Critical Noevir Co., Ltd.
Publication of WO2008029877A1 publication Critical patent/WO2008029877A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Definitions

  • Anti-aging agents whitening agents, antioxidants, and anti-inflammatory agents
  • the present invention relates to an anti-aging agent, a whitening agent, an antioxidant and an anti-inflammatory agent comprising a naturally-derived ingredient as an active ingredient, and more particularly to the use of Glias nueberthii or an extract thereof.
  • the present invention develops naturally-derived ingredients having excellent anti-aging, whitening, antioxidant, and anti-inflammatory effects, and has anti-aging agents, whitening agents, antioxidants, and
  • An object is to provide an anti-inflammatory agent and various compositions.
  • an anti-aging agent a whitening agent, an antioxidant, and an anti-inflammatory agent, each of which has an active ingredient such as Glias nueberthii or an extract thereof.
  • composition comprising Glias nueberthii or an extract thereof.
  • Glias nueberthii (scientific name: Hibiscus tiliaceus) is an evergreen tree that belongs to the genus Fuyo of the genus Aoiaceae and is distributed in the subtropical and tropical regions south of the Ryukyu Islands.
  • Ohhamabou or its extract contains an extremely large number of components that cannot be analyzed, and it is speculated that these can act in a comprehensive manner to obtain various effects of the present invention. .
  • any part of the kingfisher may be used, but for simple use, leaves, bark, and the like may be used. At that time, an extract may be obtained using a plurality of parts. In addition, two or more extracts extracted using different solvents may be used in combination.
  • the plant may be used as it is, but considering the extraction efficiency, it is preferable to carry out the extraction after processing such as shredding, drying, and grinding.
  • Extraction methods include room temperature, cooling or warming, extraction by immersing in an arbitrary extraction solvent for a predetermined time, extraction using a distillation method such as steam distillation, or from raw plants
  • a distillation method such as steam distillation
  • Examples of the pressing method include pressing to obtain an extract. Any of these methods alone It is possible to perform extraction with a combination of two or more. Alternatively, extraction can be performed using a supercritical fluid or a subcritical fluid. In order to increase the extraction efficiency, the mixture may be stirred or homogenized in an extraction solvent. It is also possible to extract under a caloric pressure using an autoclave.
  • the extraction temperature is suitably about 5 ° C to the boiling point of the extraction solvent.
  • the extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is appropriate to set it for about 1 hour to 14 days.
  • the ratio of the plant and the solvent during the extraction is not particularly limited, but is preferably 0.5 to 5 times the solvent for the plant 1; Preferably 100 times by mass.
  • Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol and isopropanol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol and glycerin; ethyl ether and propyl ether Solvents such as ethers such as butyl acetate, butyl acetate, ethyl acetate, and the like; ketones such as acetone, ethylmethylol ketone, and the like can be used. These may be used alone or in combination of any two or more. Saline, phosphate buffer, phosphate buffered saline and the like may be used. In addition, one or more supercritical liquids and subcritical liquids such as water, carbon dioxide, ethylene, propylene, ethanol, methanol, and ammonia may be used.
  • lower alcohols such as methanol, ethanol, propanol and isopropanol
  • Extracts of ono and mabo using the above solvents may be used as they are, may be left standing for a period of time and aged, or the concentrated and dried solids may be reconstituted in water or a polar solvent. It can also be used after being dissolved. Alternatively, it may be used after performing purification treatment such as decolorization, deodorization, desalting, etc., or fractionation treatment by column chromatography or the like within a range not impairing these physiological functions.
  • the above-mentioned extract of wolfberry, its processed products and fractions can be freeze-dried after each processing and fractionation and dissolved in a solvent before use. It can also be used by being encapsulated in vesicles such as liposomes or microcapsules.
  • ono, mabo or an extract thereof has excellent anti-aging, whitening, antioxidant, and anti-inflammatory effects, and is preferably used as an anti-aging agent, whitening agent, antioxidant, and anti-inflammatory agent. Use with power S.
  • Each of these agents is not limited at all in terms of its form and the presence or absence of other ingredients as long as it contains honono, mabo or an extract thereof as an active ingredient.
  • any form such as liquid, paste, gel, solid, powder, etc. can be selected according to its use, etc., and the vehicle (excipient) necessary for obtaining the form, Solvents and other common additives (antioxidants, colorants, dispersants, etc.) can optionally be included.
  • the amount of the active ingredient, Ono, Mabou or its extract, in each agent is the total amount in terms of force S, effect, and stability that can be adjusted according to the type and purpose of use of the agent. to be, 0. 00001 ⁇ in terms of solid content; preferably from 100 mass 0/0 force Mashigu ⁇ is 0.00; is ⁇ 50 mass%!.
  • An anti-aging agent comprising ceramata or an extract thereof as an active ingredient has an excellent cell activation effect, collagen production action, and aromatase activity promotion action, and exhibits an excellent effect in improving the prevention of aging symptoms.
  • Aromatase is an enzyme that works when producing estrogen. If the production of estrogen is promoted by the action of promoting aromatase activity, the effect of female hormones on skin can be expected.
  • a whitening agent comprising ono, mabo or an extract thereof as an active ingredient has an excellent melanin production inhibitory effect and tyrosinase activity inhibitory effect, and prevents and improves pigmentation, stains, freckles, etc. Exhibits excellent whitening effect.
  • Antioxidants containing ceramia or its extract as an active ingredient have an excellent free radical scavenging effect and superoxide anion scavenging effect, which prevents skin photoaging and the like. Demonstrates oxidizing action.
  • An anti-inflammatory agent comprising wolfberry or its extract as an active ingredient has excellent hyaluronidase inhibitory effect and phospholipase A2 activity inhibitory effect, and exhibits excellent anti-inflammatory action by suppressing skin inflammation. .
  • each of these agents can be used for hair or the like as well as applied externally to the skin, and can be applied to various compositions such as an external composition and an oral composition.
  • the composition for external use includes cosmetics, external preparations for skin, quasi-drugs, external medicines, etc. It is not limited to any one category, but means all compositions applied externally to the skin or hair.
  • oral composition means any composition that can be taken orally, regardless of the type of drug, food, beverage, etc.
  • the dosage form of the composition for external use is arbitrary, and can be provided as, for example, a solubilization system such as lotion, a dispersion system such as calamine mouth lotion, or an emulsification system such as cream or emulsion.
  • a solubilization system such as lotion
  • a dispersion system such as calamine mouth lotion
  • an emulsification system such as cream or emulsion.
  • it can be provided in various dosage forms such as aerosol forms, ointments, and poultices filled with propellants.
  • various cosmetics such as emulsions, creams, lotions, lotions, packs, cosmetic liquids, cleaning agents, lipsticks, makeup cosmetics, foundations, etc .; liquids, ointments, powders, granules, aerosols, patches
  • various forms of quasi-drugs such as cataplasms and cataplasms for external use.
  • the form of the oral composition is also arbitrary, and is in a liquid form such as a liquid, syrup, or extract, or a solid such as a granule, tablet, powder, capsule, glaze, or jelly, It can be processed and used in various forms such as gummi and gum, and is not particularly limited.
  • Specific examples include general foods including beverages, health foods (supplements), functional foods, nutritional supplements, oral medicines, and quasi drugs.
  • ono, mabo or its extract should be used for food and drink, health food (supplements), quasi-drugs, functional foods, etc. for the purpose of beauty such as whitening, health maintenance or nutritional supplementation. It ’s a monkey.
  • composition such as an external composition or an oral composition includes, in addition to ohahabo or an extract thereof, a normal skin cosmetic, a hair cosmetic, a quasi-drug, depending on its use and necessity, Any component used in pharmaceutical preparations is included.
  • Oil oil (oil component), alcohols, excipients, binders, extenders, disintegrants, corrigents, pigments, colorants, emulsifiers, solubilizers, dispersants, gelling agents, plasticizers, washing Agent, UV absorber, thickener, pH adjuster, buffer, surfactant, lubricant, chelating agent, drug (medicine component), fragrance, resin, coating agent, antibacterial and antifungal agent, antiseptic Agents, preservatives, antioxidants, pH adjusters and the like.
  • other anti-aging agents, whitening agents, antioxidants, anti-inflammatory agents, or plants other than wolves or extracts thereof can be used as long as the effects of the present invention are not impaired.
  • the dosage form of food is arbitrary, and can be provided in various dosage forms such as powders, granules, capsules, liquids, etc.
  • other anti-aging agents, whitening agents, antioxidants, or anti-inflammatory agents can be used in combination as long as the effects of the present invention are not impaired.
  • the blending amount of the orphan or its extract in a composition such as an external composition or an oral composition can be adjusted according to the kind of composition, purpose of use, etc. from the total amount, 0.1 in terms of solid content 00001-50. it is preferably 0 mass%, more preferably, 0.5 0001- 25. 0 mass 0/0. Further, 0.0010 to 10% by mass is more preferable 0.000;! To 5% by mass, more preferably 0.00;! To 5% by mass, and still more preferably 0. 0;! To 5% by mass, particularly preferably 0 .;! To 5% by mass.
  • Ono and burdock leaves or bark were dried and crushed, and 50% ethanol by mass of 20 times the mass of the sample was added, followed by extraction with stirring at room temperature for 2 hours.
  • the obtained extract was filtered to remove insolubles, concentrated under reduced pressure, and lyophilized to obtain an extract.
  • burdock leaves or bark were dried and pulverized, purified water of 20 times the sample mass was added, and extracted by heating to 120 ° C for 20 minutes by autoclave. From the obtained extract, insolubles were removed by suction filtration while maintaining a high temperature state, and then freeze-dried to obtain an extract.
  • the dermis fibroblast activation action was evaluated using the ono and burdock leaf ethanol extracts obtained in Extraction Method 1 as follows.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urchin fetal serum
  • the medium was replaced with a medium containing 400 ⁇ g / ml of 3- (4,5-dimethylthio-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT reagent). Cultured for 2 hours. Then, the formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 55 Onm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • MTT reagent 3- (4,5-dimethylthio-2-thiazolyl) -2,5-diphenyltetrazolium bromide
  • the skin cell activation effect was evaluated as follows.
  • Human epidermal non-keratinized cells were seeded in a 96-well microphone mouth plate so that there were 2.0 ⁇ 10 4 cells per well.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS).
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the culture medium was replaced with a sample culture solution adjusted to the concentration of each sample shown in Table 2 using 5 mass ° / ⁇ 8 S-added DMEM medium, and further cultured for 24 hours. After removing the supernatant, the medium was replaced with a medium containing 100 gZml of MTT reagent and cultured for about 2 hours.
  • fonolemazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the ELISA method was used to quantify type I collagen secreted into the culture supernatant, and finally 2, 2 'azinobis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) against the labeled peroxidase. After adding and reacting with hydrogen peroxide, absorbance at 405 nm was measured with a microplate reader.
  • ABTS 2, 2 'azinobis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt
  • the amount of protein was measured by PIERCE BCA Protein Assay Kit, and the amount of type I collagen produced per unit protein was determined.
  • the epidermal cell collagen producing action was evaluated as follows.
  • DMEM Danolebecko modified ignore medium
  • FBS urchin fetal serum
  • sandwich ELISA using a monoclonal antibody against IV collagen (recognition site: ⁇ 2 chain) and biotinylated polyclonal antibody was used, and avidinized horseradish peru After adding xidase, color was developed with 3,3 ′, 5,5′-tetramethylbenzidine, and the absorbance at 650 nm was measured with a microplate reader.
  • the amount of protein was measured using the BCA Protein Assay Kit manufactured by PIERCE, and the amount of type IV collagen produced per unit protein was determined.
  • 2-course 6-phosphate, glucose 6-phosphate dehydrogenase, and control insect cell membrane protein mixed solution (CPY19 / MFC High Throughput Inhibitor Screening Kit, manufactured by BD Biosciences) 96 1 Add and warm to 37 ° C for 10 minutes. 15 nM CPY19 (Alomata 1ze), 50 M 7 methoxy-1 4 trifluoromethylcoumarin (substrate) solution 100 1 were added, and the mixture was heated to 37 ° C. for 30 minutes. lOOmM Tris base 75 1 was added to stop the reaction. Fluorescence measurement was performed at an excitation wavelength of 409 nm and an emission wavelength of 530 nm.
  • Normal human epidermal melanocytes were seeded on a 96-well microphone mouth plate at 3.0 ⁇ 10 4 cells per well.
  • As the seeding medium Medium 154S manufactured by Kurashiki Boseki Co., Ltd. was used. 24 After culturing for 4 hours, the medium was replaced with a sampnore medium adjusted to each sample concentration shown in Table 6 using Medium 154S, and further cultured for 48 hours. Next, the cells were completely lysed by exchanging with phosphate buffer 751 containing 1% by mass 13 ⁇ 4101-X, and 501 of which was used as a crude enzyme solution.
  • B16 mouse melanoma cells (B16F0 cells) were seeded in 90 mm dishes so that there were 1 ⁇ 8 ⁇ 10 4 cells per dish.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS).
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the sample culture solution was adjusted to the concentration of each sample shown in Table 7 using 5-medium i% FBS-added DMEM medium, and further cultured for 5 days.
  • the cells were detached by trypsin treatment, transferred to a 1.5 ml microtube, and centrifuged to obtain a cell precipitate. The color of the resulting precipitate was visually judged based on the following criteria for blackening.
  • the evaluation is based on a 5-step evaluation, 5 mass ° / ( ⁇ 83 added DME M medium with no sample added to the negative control (judgment 5), 5% FBS-added DMEM medium containing 50 mM sodium lactate in the positive control (judgment 1) was used.
  • the cell lysing agent Solvable Perkin Elma Japan Co., Ltd.
  • spectrophotometer manufactured by Hitachi High-Technologies Corporation
  • the extinction rate of DPPH radical was calculated from the following equation, where (A) is the absorbance when the sample is not applied and (B) is the absorbance when the sample is added.
  • Radical scavenging rate ⁇ 1 (B) / (A) ⁇ X 100
  • the SOD-like activity was evaluated using the ono and burdock leaf ethanol extracts obtained by Extraction Method 1 as follows.
  • HANK 'S (+) solution 7 511 1 containing 25 mM WST—1 and ImM Hypoxanthine was added to the sample solution 25 5 1 prepared with the HANK' S (+) solution at each sample concentration shown in Table 9. did. Further, xanthine oxidase 25 ⁇ 1 (0.00 0075 Units) was added and reacted at 37 ° C for 15 minutes, and then the absorbance at 450 nm was measured.
  • the absorbance when only the HANK 'S (+) solution is added instead of the sample solution is (A) and the absorbance when the sample solution is added is (B)
  • the superoxide anion elimination rate is expressed by the following equation: Defined.
  • PHA phospholipase A
  • Phospholipase A adjusted to a final concentration of 60 ng / ml and the concentrations shown in Table 10
  • the Oohambobo extract has an excellent PLA enzyme inhibitory action.
  • the hyonuronidase inhibitory action was evaluated using the ono and burdock leaf ethanol extracts obtained by Extraction Method 1 as follows.
  • a commercially available hyaluronic acid potassium salt (derived from human umbilical cord) was dissolved in 0.1 M phosphate buffer ( ⁇ 7.0) so as to be 0.9 mg / ml to obtain a substrate solution.
  • a commercially available hyaluronidase (derived from urchin testis) was dissolved in 0.1 M phosphate buffer (pH 7.0) so as to be 5,300 unit / ml to obtain an enzyme solution. The enzyme solution was prepared at the time of use.
  • a sample solution (0.1 ml) and an enzyme solution (0.03 ml) prepared to each sample concentration shown in Table 11 with a buffer solution were placed in a test tube and reacted at 37 ° C for 20 minutes.
  • 0.06 ml of an activator was added and reacted at 37 ° C for 20 minutes.
  • 0.15 ml of the substrate solution was added and reacted at 37 ° C for 1 hour. Stop the reaction by adding 0.06 ml of 4N NaOH aqueous solution, then immediately ice-cool, add 0.06 ml of borate buffer (pH 9.1), boil for 3 minutes, and further ice-cool. did.
  • Carboxybule polymer (1% by weight aqueous solution) 1 5. 0
  • Carboxyvinyl polymer 0.5 (mass./.)
  • Polyoxyethylene (60 EO) hardened coconut oil 7 coconut oil 1.0 Manufacturing method: Add (1) to (2) and stir uniformly, then add (3). After stirring uniformly Add (5) dissolved in (4) in advance, and after stirring uniformly, add (6) to (8) previously mixed and stir and mix uniformly.
  • Yellowtail extract (Extraction method 2, bark) 5.0 Manufacturing method: The oil phase component of (14) is heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C and mixed with the oil phase components uniformly. Start cooling, add (8) at 40 ° C, and mix uniformly.
  • Fragrance Manufacturing method Mix and homogenize components (1) to (4).
  • Wolves extract (extraction method, leaves) Production method After mixing the powders of (1) to (3), they are pulverized by a pulverizer and uniformly dispersed.
  • Fragrance Manufacturing method (1) and (2) are heated, mixed, homogenized and cooled, then components (3) and (4) are added at 70 ° C, mixed and homogenized, and then molded.
  • an anti-aging agent a whitening agent, an antioxidant, and an anti-inflammatory agent having excellent effects can be provided by using ono, mabo or an extract thereof as an active ingredient. wear.
  • ono, mabo, or its extract into skin preparations (or compositions for external use) such as cosmetics and topical pharmaceuticals, and oral compositions such as foods, it is possible to remove wrinkles, tarmi and skin. It is possible to provide various compositions that exhibit excellent effects in preventing the appearance of various skin symptoms such as skin elasticity, skin weakness, spots and dullness.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention a pour objet un agent anti-vieillissement, un agent de blanchiment cutané, un agent antioxydant et un agent anti-inflammatoire, chacun contenant la plante Glias nueberthii ou un extrait en tant que principe actif. L'invention concerne également diverses compositions contenant la plante Glias nueberthii ou un extrait.
PCT/JP2007/067402 2006-09-06 2007-09-06 agent anti-vieillissement, agent de blanchiment cutané, agent antioxydant et agent anti-inflammatoire WO2008029877A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006241623A JP2008063266A (ja) 2006-09-06 2006-09-06 抗老化剤、美白剤、抗酸化剤、および抗炎症剤
JP2006-241623 2006-09-06

Publications (1)

Publication Number Publication Date
WO2008029877A1 true WO2008029877A1 (fr) 2008-03-13

Family

ID=39157302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/067402 WO2008029877A1 (fr) 2006-09-06 2007-09-06 agent anti-vieillissement, agent de blanchiment cutané, agent antioxydant et agent anti-inflammatoire

Country Status (2)

Country Link
JP (1) JP2008063266A (fr)
WO (1) WO2008029877A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770148A (zh) * 2009-12-10 2012-11-07 库克岛医学技术有限公司 用于骨和软骨修复的方法和组合物
CN103301253A (zh) * 2013-05-10 2013-09-18 李志立 一种中草药排毒粉剂
US20140106009A1 (en) * 2010-11-03 2014-04-17 Cimtech Pty Limited Methods and compositions for maintaining and improving the health of skin

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942721B1 (fr) * 2009-03-09 2013-02-01 Peaux Cibles Procede de traitement cosmetique et pharmaceutique destine a reduire a la fois les rides et augmenter la fermete sans provoquer de lipolyse et compositions pour sa mise en oeuvre
FR2943542B1 (fr) * 2009-03-31 2012-05-25 Lvmh Rech Methode de soin cosmetique anti-age par stimulation de l'activite de l'aconisate mitochondriale.
JP6771853B2 (ja) * 2014-03-31 2020-10-21 小林製薬株式会社 ビタミンｂ６含有組成物
JP7244004B2 (ja) * 2018-04-26 2023-03-22 共栄化学工業株式会社 皮膚外用剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5799517A (en) * 1980-12-13 1982-06-21 Tanpei Seiyaku Kk Skin protecting agent
JP2001220320A (ja) * 2000-02-09 2001-08-14 Mandom Corp 育毛剤組成物
JP2006347925A (ja) * 2005-06-14 2006-12-28 Kyoei Kagaku Kogyo Kk 植物発酵物及びこれを含む化粧料

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5799517A (en) * 1980-12-13 1982-06-21 Tanpei Seiyaku Kk Skin protecting agent
JP2001220320A (ja) * 2000-02-09 2001-08-14 Mandom Corp 育毛剤組成物
JP2006347925A (ja) * 2005-06-14 2006-12-28 Kyoei Kagaku Kogyo Kk 植物発酵物及びこれを含む化粧料

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASUDA ET AL.: "Evaluation of the antioxidant activity of environmental plants: Activity of the leaf extracts from seashore plants", J. AGRIC. FOOD CHEM., vol. 47, no. 4, 1999, pages 1749 - 1754, XP003021611 *
MASUDA ET AL.: "Screening for tyrosinase inhibitors among extracts of seashore plants and identification of potent inhibitors from Garcinia subelliptica", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 69, no. 1, 2005, pages 197 - 201, XP003021612 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770148A (zh) * 2009-12-10 2012-11-07 库克岛医学技术有限公司 用于骨和软骨修复的方法和组合物
US9750777B2 (en) 2009-12-10 2017-09-05 Cimtech Pty Limited Methods and compositions for bone and cartilage repair
US20140106009A1 (en) * 2010-11-03 2014-04-17 Cimtech Pty Limited Methods and compositions for maintaining and improving the health of skin
CN103301253A (zh) * 2013-05-10 2013-09-18 李志立 一种中草药排毒粉剂

Also Published As

Publication number Publication date
JP2008063266A (ja) 2008-03-21

Similar Documents

Publication Publication Date Title
WO2008029877A1 (fr) agent anti-vieillissement, agent de blanchiment cutané, agent antioxydant et agent anti-inflammatoire
KR20170132388A (ko) 애기수영 또는 산수국의 추출물을 유효성분으로 함유하는 주름개선 또는 피부미백용 조성물
TW201210633A (en) Agent for promoting hyaluronic acid production
JP5557414B2 (ja) 保湿剤、細胞賦活剤、及び美白剤
WO2008029798A1 (fr) Activateur cellulaire, promoteur de la production de collagène, agent blanchissant la peau, agent anti-oxydant, agent anti-inflammatoire, promoteur de l'activité aromatase, promoteur de l'activité protéase, préparation externe pour la peau et aliment
JP2011055837A (ja) 美容用飲食品
JP2010150207A (ja) 保湿剤、抗老化剤、抗酸化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、経口用剤
JP5610681B2 (ja) 中性脂肪蓄積抑制剤
JP5306605B2 (ja) 皮膚外用剤
JP5014343B2 (ja) ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤
WO2008035583A1 (fr) Agent hydratant, agent d'activation cellulaire, agent anti-oxydant, agent renforçant l'activité de la protéase, agent anti-vieillissement, agent blanchissant la peau, agent anti-inflammatoire et agent neutre inhibant l'accumulation de graisse
JP4201091B1 (ja) 保湿剤、抗老化剤、抗酸化剤及び皮膚外用剤
JP5465037B2 (ja) 抗老化剤、抗酸化剤、美白剤、免疫賦活剤、皮膚外用剤および機能性経口組成物
JP5025201B2 (ja) 保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤
JP5247548B2 (ja) 保湿剤、抗老化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、皮膚外用剤、経口用剤
JP5294847B2 (ja) 保湿剤、美白剤及び痩身剤
JP2003176232A (ja) 皮膚外用剤及び飲食品
KR102283528B1 (ko) 상온발효 가능한 엔테로코쿠스 파에시움 mss2 유산균을 이용한 곡류 및 해조류 혼합 발효 추출물을 유효성분으로 포함하는 화장료 조성물
KR101940052B1 (ko) 포제 추출물을 포함하는 조성물
JP4970442B2 (ja) 美白剤
JP5550929B2 (ja) 保湿剤、抗老化剤、抗酸化剤、美白剤、抗炎症剤、皮膚外用剤及び機能性経口組成物
JP5388555B2 (ja) 保湿剤、抗老化剤、抗酸化剤、痩身剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、機能性経口組成物
JP5610846B2 (ja) 抗老化剤、抗酸化剤、抗炎症剤、美白剤、保湿剤、皮膚外用剤および機能性経口組成物
JP5265489B2 (ja) 保湿剤、抗老化剤、抗酸化剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、経口用剤
JP5241395B2 (ja) 保湿剤、免疫賦活剤、抗老化剤、抗炎症剤、抗酸化剤、美白剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07806843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07806843

Country of ref document: EP

Kind code of ref document: A1